Prognosis of patients with metastatic soft tissue sarcoma remains poor. Whether high-dose chemotherapy with stem cell support improves the long-term outcome for these patients is debatable. We present a prospective, singleinstitutional phase II study that enrolled 34 soft tissue sarcoma patients with advanced and/or metastatic disease. After four courses of chemotherapy consisting of doxorubicin and ifosfamide, responding patients in at least partial response (PR) were treated with high-dose chemotherapy (n ¼ 9); all other patients continued chemotherapy for two more cycles. After standard chemotherapy, PR (n ¼ 10), stable disease (SD, n ¼ 6) and progressive disease (PD, n ¼ 14) were attained for the evaluable patients. Twenty-nine patients died and five are alive with the disease. Median PFS was 11.6 months (range 8-15) for patients treated with high-dose chemotherapy (n ¼ 9) vs 5.6 months (range 0-19) for patients treated with standard chemotherapy. Median OS was 23.7 months (range 12-34) vs 10.8 months (range 0-39), respectively. The subgroup of patients treated with highdose chemotherapy gained significant survival benefit. Nevertheless, high-dose chemotherapy as a possible consolidation strategy remains highly investigational.
Introduction
Soft tissue sarcomas (STSs) are rare mesenchymal neoplasms that arise from the embryonic mesoderm. They constitute less than 1% of all adult malignancies affecting all age groups. The prognosis of patients with advanced and/or metastatic disease remains poor with a disease-free survival at 5 years less than 10%, mostly because of metastases involving the lungs. [1] [2] [3] [4] About 10% of the patients present with metastatic disease at the time of diagnosis, whereas 40-60% of patients with high-grade sarcoma will develop metastases despite local control of the tumor. Median survival from the time of diagnosis for metastatic disease is 8-12 months.
Doxorubicin and ifosfamide are the most active single agents in the treatment of STSs with response rates above 20%. [5] [6] [7] For the anthracyclines and ifosfamide, a dose response has been well documented. [8] [9] [10] [11] In phase II studies, different combination regimens based on high doses of ifosfamide, doxorubicin or cisplatin showed response rates of up to 60%. 12, 13 However, consecutive phase III trials showed inconsistent benefits in terms of response rates, and hence an improvement in overall survival could not be shown. 2, 3 Whether high-dose chemotherapy improves the results in adult sarcoma patients is still controversial. [14] [15] [16] [17] [18] Literature is scarce and difficulties arise because of the rather small numbers of patients enrolled in the performed studies, because of comparing different histologies or treatment strategies, and because of the nearly complete lack of randomized trials. Certain trials showed improved long-term, relapse-free survival compared with historical controls, whereas other studies suggested that selection biases may account for such improvements. 19 Reichardt 20 concluded that studies are usually small and comprise heterogeneous groups of patients. Therefore, high-dose chemotherapy in STSs has to be considered highly investigational and should not be performed outside clinical trials. Blay 21 published the largest homogeneous phase II study in 30 patients with metastatic STS using a high-dose chemotherapy regimen consisting of etoposide, ifosfamide and cisplatin. They could show a median OS of 19 months and a PFS of 7 months, with yielded response rates ranging between 18% and 66%. Some of the patients with advanced-stage STS achieved long-term CR, in particular the subgroup of patients in CR after conventional chemotherapy. 22 There is a large database collected by the European Group for Blood and Marrow Transplantation including over 280 patients with STS. 23 Nevertheless, more than 200 of the reported tumors are childhood rhabdomyosarcomas and are therefore not comparable to adult STS. The study by Schlemmer et al. 24 treated 19 chemosensitive STS patients in CR or partial response (PR) with high-dose chemotherapy and stem cell rescue. Although the 5-year PFS was significantly higher for patients allocated to highdose chemotherapy compared with patients receiving second-line chemotherapy, the 5-year OS failed to show a significant difference between the two groups. Blay et al. 25 of the French Sarcoma Group presented the first randomized trial including 21 patients treated with high-dose chemotherapy. The 3-year OS was 45.5% for the control arm vs 35.8% for the high-dose arm. The authors concluded that high-dose chemotherapy did not improve disease-free survival or OS. 25 This article describes a prospective phase II study evaluating the impact of high-dose chemotherapy and stem cell support in the treatment of advanced STS patients and focuses on the possible implications and restrictions of this treatment option.
Patients and methods

Patients
The data of 34 patients with STS were analyzed and enrolled in a prospective single-centre, nonrandomized trial between November 2003 and April 2008 at the Department of Internal Medicine V, University of Heidelberg, Germany. Patients' characteristics, including age at transplantation, histology, metastatic sites and disease, as well as survival status, are summarized in Table 1 . The research was carried out according to the principles set out in the Declaration of Helsinki in 1964 and all subsequent revisions. The study design was approved by the relevant institutional review board and written informed consent was obtained from all patients before participation in the study. All histological diagnoses were reviewed by the local pathologist or by a reference pathologist. Histologies included leiomyosarcoma (n ¼ 7), synovial sarcoma (n ¼ 4), liposarcoma (n ¼ 4), malignant fibrous histiocytoma (MFH, 'undifferentiated high-grade pleomorphic sarcoma' according to the World Health Organization (WHO) 
, meningosarcoma (n ¼ 1), and not otherwise specified (NOS) sarcomas (n ¼ 7). Histopathology grading according to the Fe´de´ration Nationale des Centres de Lutte Contre le Cancer (FNCLCC) system revealed G III (n ¼ 27) and G II (n ¼ 7) tumors. In all, 20 patients were female and 14 were male. Eligibility criteria for the study were primary or recurrent metastatic STS; no patients with unresectable disease were included. Twenty-eight patients showed recurrent disease before the study inclusion; six patients were entered with a new diagnosis of primary metastatic STS. For the recurrent patients, prior treatments included surgery (n ¼ 27), radiotherapy (n ¼ 9) and chemotherapy (n ¼ 2). Median age at the time of PBSC transplantation was 46 years (range 29-65). Normal creatinine, normal cardiac function and normal bilirubin levels were required before high-dose chemotherapy. Median CD34 þ cell count at PBSC transplantation was 3.96 Â 10 6 CD34 þ cells per kg body weight (range 2.3-7.7). Following conventional chemotherapy with doxorubicin and ifosfamide, PR (n ¼ 10), stable disease (SD, n ¼ 6) and progressive disease (PD, n ¼ 14) were reached; four patients were not evaluable regarding response status.
Chemotherapy
Patients were treated according to the flow chart depicted in Figure 1 . Responding patients in PR (n ¼ 9) received high-dose chemotherapy and autologous stem cell support, whereas all other patients were treated with conventional chemotherapy. As standard induction chemotherapy, all patients received a regimen consisting of doxorubicin 75 mg/m 2 on day 1 and ifosfamide 1500 mg/m 2 on days 1-4, which was repeated on day 22 for a maximum of six cycles (AI-G). For high-dose chemotherapy (n ¼ 9), the conditioning regimen ICE was used consisting of ifosfamide 2000 mg/m 2 administered on days 1-6, carboplatin 200 mg/m 2 per days 1-6 and etoposide 200 mg/m 2 per days 1-6. Mesna was given if necessary as 24 h continuous infusion. Hydration comprised normal saline (0.9%) about 2 l/m 2 and dextrose 5%. In case of grade I or higher renal toxicity, hydration volume was increased until serum creatinine levels fell. Patients received haematopoietic SCT 2 days after the end of high-dose chemotherapy if creatinine levels were normal. No other chemotherapy was given until relapse.
Statistical analysis
No patients were lost to follow-up. Statistical analysis of the data was performed using the statistical software SPSS (SPSS Inc., Chicago, IL, USA). Median PFS and OS were assessed from the time of study inclusion; values are given as median and range. Survival curves were generated according to the Kaplan-Meier method; P-values were calculated using the log rank test.
Results
Response status
Response status was assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST). All patients were examined using computed tomography and/ or magnetic resonance imaging before therapy and after four cycles of standard chemotherapy consisting of doxorubicin and ifosfamide. Following conventional chemotherapy the response status was as follows: PR (n ¼ 10), SD (n ¼ 6) and PD (n ¼ 14); four patients were not evaluable regarding response status. Of the ten responding patients in PR, nine were treated with high-dose chemotherapy and stem cell support (cases 4, 7, 11, 12, 14, 21, 25, 26 and 30; Table 1 ); one patient (case 28) refused treatment with auto-SCT (compare Table 1 ).
Survival data
Median PFS from the date of study entry for all 34 patients enrolled in the prospective trial was 7.2 months (range 0-19); median OS was 14.2 months (range 0-34), respectively. Meanwhile, 27 patients died of disease (DOD), two died from other causes (DOC), five are still alive with disease (AWD). For patients treated with high-dose chemotherapy (n ¼ 9), median PFS was 11.6 months (range 8-15) vs 5.6 months (range 0-19) for patients treated with standard chemotherapy (n ¼ 25). Median OS was 23.7 months (range 12-34) vs 10.8 months (range 0-39), respectively. Kaplan-Meier survival curves for PFS and OS comparing the two populations are depicted in Figure 2 . A significant difference could be shown regarding PFS (P ¼ 0.047) and OS (P ¼ 0.027) for the subgroup of responding patients being treated with high-dose chemotherapy and stem cell support. After completing conventional chemotherapy/high-dose chemotherapy, additional treatments included surgery of the primary tumor and/or metastases (n ¼ 11), radiotherapy (n ¼ 4) and different chemotherapy regimens, including trofosfamide, 21) . Owing to the low number of patients receiving high-dose chemotherapy and the heterogeneity of additional treatments for further disease progression, no further conclusions could be drawn regarding disease response evaluation or resectability rate after high-dose chemotherapy.
Toxicity
All patients receiving an autologous PBSC graft experienced WHO grade IV leukocytopenia, neutropenia and thrombocytopenia. There were two deaths from other causes (DOC): one patient in remission died because of a pulmonary infection 12 months after the start of the treatment (case 7); another patient died during standard chemotherapy because of a myocardial infarction (case 22).
Discussion
Although few sarcoma subtypes such as rhabdomyosarcomas, tumors from the Ewing sarcoma family and synovial sarcomas are chemosensitive, most STSs respond poorly to chemotherapy with CR rates hardly exceeding 10%. To improve the prognosis of sarcoma patients, a reasonable goal could be to increase the CR rate by treating patients with higher doses of chemotherapy and autologous stem cell support. However, high-dose chemotherapy has been studied only in small and inconclusive studies so far. Moreover, only one randomized phase III trial from the French Sarcoma Group exists. 25 Therefore, the use of highdose chemotherapy for advanced and/or metastatic adult STS patients still remains highly investigational and should not be performed outside clinical trials. We have discussed the possible implications and restrictions of this treatment option in former works of our group. [26] [27] [28] This paper describes a large single-institution collective of STS patients treated within a prospective, nonrandomized trial using high-dose chemotherapy and stem cell support. A significant difference regarding PFS (P ¼ 0.047) and OS (P ¼ 0.027) could be shown for the subgroup of responding patients in PR who were treated with high-dose chemotherapy and stem cell support (Figure 2) . Therefore, our results are in line with the data of the French Sarcoma Group around Blay. 21 With a median PFS of 11.6 months and a median OS of 23.7 months, we could even show longer survival compared with the published data. One major limitation of our study is of course the relatively heterogeneous patient population regarding histology. Interestingly, Blay et al. found a significantly better outcome for patients in CR before high-dose chemotherapy. We could validate these findings as we could also show improved median PFS and OS for patients treated with high-dose chemotherapy. However, survival benefit could only be due to the selection of favorable patients for this special treatment, because only responding patients in PR were proposed for high-dose chemotherapy. The only randomized phase III trial that has been presented by the French Sarcoma Group at this year's Annual Meeting of the American Society of Clinical Oncology failed to show any survival benefit for STS patients treated with high-dose chemotherapy. 25 Limitations of this study have been the low accrual, new treatment concepts, and the fact that only 21 from the 87 randomized patients actually received high-dose chemotherapy. The 3-year OS was 45.5% for the control arm vs 35.8% for the high-dose arm, leading to the conclusion that high-dose chemotherapy did not improve disease-free survival or OS; consolidation strategies with new concepts have to be explored.
Conclusion and summary
Our data suggest that high-dose chemotherapy with stem cell support may improve the median PFS and OS of individual STS patients, probably only reflecting chemoresponse. However, this question could only be addressed through a randomized study. In our as well as other series, long-term survival after high-dose chemotherapy was rarely observed in patients presenting with less than PR. Therefore, this strategy remains palliative and should not be performed outside clinical trials. Possible candidates for high-dose chemotherapy could be younger patients with a good performance status in CR or PR before high-dose chemotherapy. As the randomized study from the French Sarcoma Group failed to show any survival benefit, consolidation strategies with new concepts have to be explored in the future. High-dose chemotherapy for chemosensitive STS patients B Kasper et al
